University of Calgary
Calgary, Alberta, T2N 4Z6, Canada
NCT Number: NCT02579655
The purpose of this study is to determine the effect of two novel interventions; (1) a value-based formulary which eliminates copayment for selected high-value medications (proven to prevent heart attacks, stroke, and hospitalizations); and (2) a comprehensive patient education program aimed at lifestyle modification and optimal drug use, combined with relay of information on medication use, on the risk of adverse clinical outcomes (mortality, heart attack, stroke, need for coronary revascularization, and chronic disease related hospitalizations) in low-income seniors with chronic conditions over three years of follow-up or until March 31, 2021 (whichever comes first).
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Calgary, Alberta, T2N 4Z6, Canada
Chronic diseases, such as stroke, myocardial infarction, hypertension, diabetes and chronic kidney disease, are the major challenge facing health care systems worldwide. Although medications and lifestyle changes can improve the health of these patients, many do not benefit from these treatments due to barriers at the level of the patient, provider and/or health system, resulting in a care gap. Multiple barriers may contribute to the observed care gap for patients with these chronic diseases-but prior research has identified that 1) out-of-pocket costs for medications (including co-payments); and 2) lack of patient knowledge about the potential benefits of treatment are particularly important. Although these barriers clearly compromise outcomes among people with chronic diseases, the best way to overcome them and close the care gap is uncertain.
In the ACCESS trial, the investigators will study the effect of two novel interventions in 4764 participants with chronic disease. The investigators hypothesize that (1) eliminating copayments for high value cardioprotective medications and (2) a comprehensive patient education program on optimal medication use, combined with relay of information on optimal medication use by the patient to their health care provider, will decrease the risk of adverse clinical outcomes during the follow-up period.
Methods and study design: Parallel, open label, factorial randomized controlled trial with blinded endpoint evaluation assessing the impact of two interventions: 1) elimination of patient copayment for selected medications, and 2) patient education with relay of information to the participant's health care provider.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
>65 years of age (have drug insurance from Alberta Blue Cross with 30% copayment)
Have any one of the following:
OR any two of the following:
Have total family income <$50,000
Exclusion criteria
Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
See below for definitions of individual components for this composite outcome.
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
Die (y/n)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
Nonfatal MI based on administrative data (y/n)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
Nonfatal stroke based on administrative data (y/n)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
Coronary revascularization (angioplasty or bypass surgery) based on administrative data (y/n)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
hospitalizations for chronic disease-related ambulatory care sensitive conditions based on administrative data (y/n)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
Full adherence to statins will be measured using the proportion of days covered, which is estimated by the "number of days dispensed" / "number of days between prescription renewals" using Alberta Blue Cross data. Patients that have a dispensed supply of statins to cover at least 80% of observed treatment days will be considered adherent (Y/N)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
Index score ranges from 0 to 1 (full health)
Time frame: 3 years or until March 31, 2021 (for patients enrolled after March 31, 2018)
All costs (cost of interventions taken from study data, and costs of all health care encounters taken from Alberta Health administrative data using grouper codes) will be combined into Canadian $.
University of Calgary
Other
Acronym: ACCESS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00000542
Cardiovascular Diseases, Coronary Disease
View Trial DetailsNCT00005487
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT00049907
Brain Diseases, Cardiovascular Diseases
View Trial DetailsNCT00149435
Brain Diseases, Cardiovascular Diseases
View Trial Details